Ungual and Transungual drug delivery

Drug Development and Industrial Pharmacy

Volumn 38, Issue 8, 2012, Pages 901-911

  Shivakumar, H N ^a,b   Juluri, Abhishek ^c   Desai, B G ^a   Murthy, S Narasimha ^c  

^a A Constituent Unit of KLE Academy of Higher Education Research   (India)

^b DermaPerm Research Inc   (India)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Antifungal; in vitro models; Iontophoresis; Nail penetration; Onychomycosis; Transungual

Indexed keywords

1 METHYL 2 PYRROLIDINONE; AMOROLFINE; CHLORAMPHENICOL; CICLOPIROX; CICLOPIROXOLAMINE; CLOTRIMAZOLE; DEXPANTHENOL; DIETHYLENE GLYCOL MONOETHYL ETHER; DIMETHYL SULFOXIDE; ECONAIL; ECONAZOLE; GLUTARALDEHYDE; GRISEOFULVIN; HYDROGEN PEROXIDE; KERATOLYTIC AGENT; KETOCONAZOLE; LABRASOL; MERCAPTOETHANOL; MICONAZOLE; MONPHYTOL; NAFTIFINE; PENETRATION ENHANCING AGENT; SALICYLIC ACID; SERTACONAZOLE; SODIUM SULFITE; TERBINAFINE; THIOGLYCOLIC ACID; TIOCONAZOLE; TROSYL; UNCLASSIFIED DRUG; UNDECANOIC ACID; UNINDEXED DRUG; UREA; WATER;

DEVICES; DRUG ADMINISTRATION ROUTE; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; IONTOPHORESIS; JUGLANS REGIA; MOLECULAR SIZE; MOLECULAR WEIGHT; NAIL; NONHUMAN; PARTITION COEFFICIENT; PH; REVIEW; SURFACE CHARGE; TRANSUNGUAL DRUG DELIVERY; ULTRASOUND; UNGUAL DRUG DELIVERY;

ADMINISTRATION, TOPICAL; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; NAIL DISEASES; NAILS; PERMEABILITY;

EID: 84863448576     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.637931     Document Type: Review

References (61)

1. Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y. (1999). Drug permeation through the three layers of the human nail plate. J Pharm Pharmacol, 51:271-278.
2. Lynch MH, O'Guin WM, Hardy C, Mak L, Sun TT. (1986). Acidic and basic hair/nail ("hard") keratins: their colocalization in upper cortical and cuticle cells of the human hair follicle and their relationship to "soft" keratins. J Cell Biol, 103:2593-2606.
3. Murdan S. (2002). Drug delivery to the nail following topical application. Int J Pharm, 236:1-26.
4. Walters KA, Flynn GL. (1983). Permeability characteristics of the human nail plate. Int J Cosmet Sci, 5:231-246.
5. Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R et al. (2000). A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol, 43:641-648.
6. Sigureirsson, Steingrimsson. (2004). Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol, 18:48-51.
7. Faergemann J, Baran R. (2003). Epidemiology, clinical presentation and diagnosis of onychomycosis. Br J Dermatol, 149 Suppl 65:1-4.
8. Niewerth M, Korting HC. (1999). Management of onychomycoses. Drugs, 58:283-296.
9. de Berker D. (2009). Management of psoriatic nail disease. Semin Cutan Med Surg, 28:39-43.
10. Repka MA, O'Haver J, See CH, Gutta K, Munjal M. (2002). Nail morphology studies as assessments for onychomycosis treatment modalities. Int J Pharm, 245:25-36.
11. Scher RK. (1999). Onychomycosis: therapeutic update. J Am Acad Dermatol, 40:21-26.
12. Brown MB, Khengar RH, Turner RB, Forbes B, Traynor MJ, Evans CR et al. (2009). Overcoming the nail barrier: A systematic investigation of ungual chemical penetration enhancement. Int J Pharm, 370:61-67.
13. Hao J, Li SK. (2008). Transungual iontophoretic transport of polar neutral and positively charged model permeants: efects of electrophoresis and electroosmosis. J Pharm Sci, 97:893-905.
14. Murthy SN, Vaka SR, Sammeta SM, Nair AB. (2009). TranScreen-N: Method for rapid screening of trans-ungual drug delivery enhancers. J Pharm Sci, 98:4264-4271.
15. Murthy SN, Waddell DC, Shivakumar HN, Balaji A, Bowers CP. (2007). Iontophoretic permselective property of human nail. J Dermatol Sci, 46:150-152.
16. Narasimha Murthy S, Wiskirchen DE, Bowers CP. (2007). Iontophoretic drug delivery across human nail. J Pharm Sci, 96:305-311.
17. Quintanar-Guerrero D, Ganem-Quintanar A, Tapia-Olguín P, Kalia YN, Buri P. (1998). The efect of keratolytic agents on the permeability of three imidazole antimycotic drugs through the human nail. Drug Dev Ind Pharm, 24:685-690.
18. Smith KA, Hao J, Li SK. (2009). Efects of ionic strength on passive and iontophoretic transport of cationic permeant across human nail. Pharm Res, 26:1446-1455.
19. Smith KA, Hao J, Li SK. (2010). Infuence of pH on transungual passive and iontophoretic transport. J Pharm Sci, 99:1955-1967.
20. Vignardet C, Guillaume YC, Friedrich J, Millet J. (1999). A frst order experimental design to assess soluble proteins released by a new keratinase from Doratomyces microsporus on human substrates. Int J Pharm, 191:95-102.
21. Mertin D, Lippold BC. (1997). In-vitro permeability of the human nail and of a keratin membrane from bovine hooves: prediction of the penetration rate of antimycotics through the nail plate and their efcacy. J Pharm Pharmacol, 49:866-872.
22. Kobayashi Y, Komatsu T, Sumi M, Numajiri S, Miyamoto M, Kobayashi D et al. (2004). In vitro permeation of several drugs through the human nail plate: relationship between physicochemical properties and nail permeability of drugs. Eur J Pharm Sci, 21:471-477.
23. Malhotra GG, Zatz JL. (2002). Investigation of nail permeation enhancement by chemical modifcation using water as a probe. J Pharm Sci, 91:312-323.
24. Vejnovic I, Simmler L, Betz G. (2010). Investigation of diferent formulations for drug delivery through the nail plate. Int J Pharm, 386:185-194.
25. Nair AB, Chakraborty B, Murthy SN. (2010). Efect of polyethylene glycols on the trans-ungual delivery of terbinafne. Curr Drug Deliv, 7:407-414.
26. Nair AB, Kim HD, Davis SP, Etheredge R, Barsness M, Friden PM et al. (2009). An ex vivo toe model used to assess applicators for the iontophoretic ungual delivery of terbinafne. Pharm Res, 26:2194-2201.
27. Nair AB, Sammeta SM, Vaka SR, Narasimha Murthy S. (2009). A study on the efect of inorganic salts in transungual drug delivery of terbinafne. J Pharm Pharmacol, 61:431-437.
28. Nair AB, Vaka SR, Sammeta SM, Kim HD, Friden PM, Chakraborty B et al. (2009). Trans-ungual iontophoretic delivery of terbinafne. J Pharm Sci, 98:1788-1796.
29. Walters KA, Flynn GL, Marvel JR. (1985). Physicochemical characterization of the human nail: solvent efects on the permeation of homologous alcohols. J Pharm Pharmacol, 37:771-775.
30. Marro D, Guy RH, Delgado-Charro MB. (2001). Characterization of the iontophoretic permselectivity properties of human and pig skin. J Control Release, 70:213-217.
31. de Berker D. (2009). Clinical practice. Fungal nail disease. N Engl J Med, 360:2108-2116.
32. Neev J, Nelson JS, Critelli M, McCullough JL, Cheung E, Carrasco WA et al. (1997). Ablation of human nail by pulsed lasers. Lasers Surg Med, 21:186-192.
33. Salter SA, Ciocon DH, Gowrishankar TR, Kimball AB. (2006). Controlled nail trephination for subungual hematoma. Am J Emerg Med, 24:875-877.
34. Ciocon D, Gowrishankar TR, Herndon T, Kimball AB. (2006). How low should you go: novel device for nail trephination. Dermatol Surg, 32:828-833.
35. Boker A, Ciocon D, Kimbell A. (2007). A randomized, double-blind placebo-controlled, pilot study of 1% terbinafne cream applied twice daily and delivered via nail plate microporation for the treatment of subungual toenail trephination. J Am Acad Dermatol, 56, AB 114.
36. Murdan S. (2008). Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv, 5:1267-1282.
37. Khengar RH, Jones SA, Turner RB, Forbes B, Brown MB. (2007). Nail swelling as a pre-formulation screen for the selection and optimisation of ungual penetration enhancers. Pharm Res, 24:2207-2212.
38. Sun Y, Liu JC, Wang JCT, De Doncker P. (1999). Nail penetration. Focus on topical delivery of antifungal drugs for onychomycosis treatment. In Bronaugh RL, Maibach HI, eds. Percutaneous absorption Drugs-Cosmetics-Mechanisms- Methodology. NewYork: Marcel Dekker Inc., 759-787.
39. Kobayashi Y, Miyamoto M, Sugibayashi K, Morimoto Y. (1998). Enhancing efect of N-acetyl-l-cysteine or 2-mercaptoethanol on the in vitro permeation of 5-fuorouracil or tolnaftate through the human nail plate. Chem Pharm Bull, 46:1797-1802.
40. Baran R, Tosti A. (2002). Chemical avulsion with urea nail lacquer. J Dermatolog Treat, 13:161-164.
41. Mohorcic M, Torkar A, Friedrich J, Kristl J, Murdan S. (2007). An investigation into keratinolytic enzymes to enhance ungual drug delivery. Int J Pharm, 332:196-201.
42. Hay RJ, Clayton YM, Moore MK. (1987). A comparison of tioconazole 28% nail solution versus base as an adjunct to oral griseofulvin in patients with onychomycosis. Clin Exp Dermatol, 12:175-177.
43. Hui X, Shainhouse Z, Tanojo H, Anigbogu A, Markus GE, Maibach HI et al. (2002). Enhanced human nail drug delivery: nail inner drug content assayed by new unique method. J Pharm Sci, 91:189-195.
44. Hui X, Baker SJ, Wester RC, Barbadillo S, Cashmore AK, Sanders V et al. (2007). In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci, 96: 2622-2631.
45. Suringa DW. (1970). Treatment of superfcial onychomycosis with topically applied glutaraldehyde. A preliminary study. Arch Dermatol, 102:163-167.
46. Marty J-L. (1995). Amorolfne nail lacquer: a novel formulation. J Eur Acad of Dermatol Venereol, 4 (Suppl 1) S17-S21.
47. Franz TJ. (1992). Absorption of amorolfne through human nail. Dermatology (Basel), 184 Suppl 1:18-20.
48. Gupta AK, Fleckman P, Baran R. (2000). Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol, 43:S70-S80.
49. Polak A. (1993). Amorolfne: A review of its mode of action and in vitro and in vivo antifungal activity. J Am Assoc South East Asia, 9 (Suppl 4):11-18.
50. Hui X, Chan TC, Barbadillo S, Lee C, Maibach HI, Wester RC. (2003). Enhanced econazole penetration into human nail by 2-n-nonyl-1,3-dioxolane. J Pharm Sci, 92:142-148.
51. Shivakumar HN, Vaka SR, Madhav NV, Chandra H, Murthy SN. (2010). Bilayered nail lacquer of terbinafne hydrochloride for treatment of onychomycosis. J Pharm Sci, 99:4267-4276.
52. Avner S, Nir N, Henri T. (2005). Combination of oral terbinafne and topical ciclopirox compared to oral terbinafne for the treatment of onychomycosis. J Dermatolog Treat, 16:327-330.
53. Van Hoogdalem EJ, van den Hoven WE, Trepstra IJ, van Zijtveld J, Verschoor JSC, Visser JN. (1997). Nail penetration of antifungal agent oxiconazole after repeated topical application in healthy volunteers, and the efect of acetylcysteine. Eur J Pharm Sci, 5:119-127.
54. Hui X, Wester RC, Barbadillo S, Lee C, Patel B, Wortzmman M et al. (2004). Ciclopirox delivery into the human nail plate. J Pharm Sci, 93:2545-2548.
55. Repka MA, Mididoddi PK, Stodghill SP. (2004). Infuence of human nail etching for the assessment of topical onychomycosis therapies. Int J Pharm, 282:95-106.
56. Obadiah J, Scher R. (2002). Nail disorders: unapproved treatments. Clin Dermatol, 20:643-648.
57. Baden HP. (1994). Treatment of distal onychomycosis with avulsion and topical antifungal agents under occlusion. Arch Dermatol, 130:558-559.
58. Mididoddi PK, Repka MA. (2007). Characterization of hot-melt extruded drug delivery systems for onychomycosis. Eur J Pharm Biopharm, 66:95-105.
59. Susilo R, Korting HC, Greb W, Strauss UP. (2006). Nail penetration of sertaconazole with a sertaconazole-containing nail patch formulation. Am J Clin Dermatol, 7:259-262.
60. Warshaw EM, St Clair KR. (2005). Prevention of onychomycosis reinfection for patients with complete cure of all 10 toenails: results of a double-blind, placebo-controlled, pilot study of prophylactic miconazole powder 2%. J Am Acad Dermatol, 53: 717-720.
61. Bindra, Rattan Lal, Singh, Anil Kumar, Shawl, Abdul Sami, Kumar, Sushil. (2001). Anti-fungal herbal formulation for treatment of human nails fungus and process thereof. United States Patent No.6296838.